AbbVie Inc. Stock
€169.55
Your prediction
AbbVie Inc. Stock
AbbVie (ABBV) is a multinational biopharmaceutical company based in North Chicago, Illinois. It was spun off as a separate entity from Abbott Laboratories in 2013 and is primarily focused on the development and commercialization of drugs for the treatment of conditions such as immunology, oncology, and neuroscience. Its key product is Humira, which is used to treat a range of autoimmune diseases, generating a significant portion of the company's revenue. The company also has a pipeline of promising products in various stages of development, making it a reputable player in the pharmaceutical industry.
Pros and Cons of AbbVie Inc. in the next few years
Pros
Cons
Performance of AbbVie Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | -1.480% | -4.263% | -4.317% | 6.904% | -13.671% | 14.098% | 84.093% |
| BioMarin Pharmaceutical Inc. | -1.750% | -2.304% | -2.848% | -17.629% | -10.864% | -47.910% | -30.243% |
| Biogen Inc. | -2.650% | 4.393% | -0.913% | 49.881% | 4.972% | -40.731% | -27.562% |
| Zoetis Inc. A | 0.240% | -4.115% | -0.360% | -25.449% | -7.116% | -37.577% | -29.252% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of AbbVie (ABBV) reveals a company that exhibits both promising strengths and notable challenges. The pharmaceutical giant has managed to sustain significant revenue levels and maintain a relatively solid position within the industry. However, certain metrics highlight potential concerns regarding profitability and debt that merit careful consideration.
Robust Revenue Generation: AbbVie reported total revenue reaching approximately $54.99 billion over the last twelve months (TTM). This impressive figure underscores the company's ability to generate consistent sales, primarily driven by its product portfolio, notably immunology and oncology drugs.
Substantial EBITDA Margin: The EBITDA stands at around $26.25 billion, indicating a solid operational performance in generating earnings before interest, taxes, depreciation, and amortization. With an EBITDA margin of about 47.7%, AbbVie showcases its competent operational efficiency, allowing it to retain a significant portion of its revenue as earnings.
Comments
News
Why AbbVie Is a No-Brainer Stock to Buy on the Dip
AbbVie's (NYSE: ABBV) stock closed at a record high of $238.71 on Oct. 1, 2025. However, its stock has pulled back by about 13% since then. Let's see why that pullback represents a golden buying
Could AbbVie Crash Lilly's Weight‑Loss Party?
AbbVie's (NYSE: ABBV) most important therapeutic area has historically been immunology, where it has marketed billion-dollar drugs like Humira, which was once the world's best-selling medicine. The
S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend.
Don't look now, but the S&P 500 index is becoming something of a desert for income investors. As reported recently by Yahoo! Finance, the average dividend yield of all 500 titles has shriveled to